# ENYO Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enyo-pharma

- Industry: Pharmaceuticals
- Headquarters: Lyon, France
- Website: www.enyopharma.com
- Total disclosed funding: $31M
- Latest round: Series C (Jan 19, 2024)
- Investors on record: 10

## About

Founded in 2014 and based in Lyon, France, ENYO Pharma SA operates as a developer of drug treatments using fibrolytic and anti-inflammatory qualities for illnesses with compromised kidney function. The company's headquarters is located in Lyon, France, a hub of biomedical innovation, with additional research and development facilities in the United States and the United Kingdom. In January 2024, ENYO Pharma SA raised EUR 7 million in series C funding co-led by returning investor OrbiMed and new investor Morningside Ventures with participation from other returning investors Andera Partners, Bpifrance InnoBio, and CDC Enterprises.

Enyo Pharma's product pipeline is focused on the development of novel small-molecule and biologic therapies for a range of complex and rare diseases, including liver diseases, metabolic disorders, and autoimmune conditions. One of Enyo Pharma's lead product candidates is a first-in-class small-molecule therapy for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease that is becoming increasingly prevalent globally. This investigational therapy has demonstrated promising results in preclinical studies and is currently undergoing clinical evaluation. In addition to its NASH program, Enyo Pharma is also advancing several other drug candidates targeting a variety of disease areas, including rare genetic disorders and chronic inflammatory conditions.

Enyo Pharma generates revenue primarily through research and development collaborations, licensing agreements, and government grants.

## Funding rounds

- Series C, Jan 19, 2024, $7.2M — OrbiMed Advisors, CDC Enterprises, Andera Partners, 5Y Capital, InnoBio Ventures
- Series B, Dec 2, 2020, $17M — OrbiMed Advisors, Sofinnova Partners, Andera Partners, 5Y Capital, InnoBio Ventures, Inserm Transfert Initiative, Bpifrance Investissement, Morningside
- Series A, Mar 3, 2016, $6.6M — Sofinnova Partners, Inserm Transfert Initiative, Bpifrance Investissement, ADV Life Sciences, Morningside

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Inserm Transfert Initiative (https://capitalatlas.ai/funds/inserm-transfert-initiative) — Series A, Series B
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A, Series B
- ADV Life Sciences — Series A
- Morningside (https://capitalatlas.ai/funds/morningside) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B, Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B, Series C
- InnoBio Ventures — Series B, Series C
- CDC Enterprises (https://capitalatlas.ai/funds/cdc-enterprises) — Series C